Filing Flows › Opus Genetics (IRD) › Q3 2025
Opus Genetics (IRD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Opus Genetics (IRD) reported revenue of $3.1M for the third quarter 2025 (Q3 2025), -20% from a year earlier and +7% from the quarter before. Operating margin was -269.9%, net loss $17.5M (566.9% of revenue).
Opus Genetics, Q3 2025: revenue $3.1M (-20% year over year), operating margin -269.9%, net loss $17.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.1M | +7% | -20% |
| Operating profit | −$8.3M | — | — |
| Net earnings | −$17.5M | — | — |
| Operating cash flow | −$6.2M | — | — |
What changed
Revenue was $3.1M in Q3 2025, down 20% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $8.3M, an operating margin of -269.9%. Total costs fell 4% while revenue fell 20%. The fastest-growing cost line was General & admin (+72%). The quarter ended with a net loss of $17.5M, wider than the previous quarter's $7.4M loss. Net interest and other expense of $9.1M was the main reason.
Operating cash flow was −$6.2M. Non-cash charges added back $13K of depreciation and $816K of share-based compensation. Working capital and other items added $10.5M.
Questions
What was Opus Genetics' revenue in the third quarter 2025?
Opus Genetics (IRD) reported revenue of $3.1M for the third quarter 2025 (Q3 2025), -20% from a year earlier and +7% from the quarter before.
Was Opus Genetics profitable in the third quarter 2025?
Operating loss was $8.3M (-269.9% of revenue) and net loss $17.5M.
Source: Opus Genetics 10-Q on SEC EDGAR.